Immunic Therapeutics
Developing Selective Oral Drugs in Immunology
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.
Immunic, Inc. is headquartered in New York. Its subsidiary, Immunic AG, is based in Gräfelfing near Munich, Germany, where the company’s research and development activities are conducted. Additional subsidiaries are located in Halle (Saale), Germany, and Melbourne, Australia.
The company is developing three small molecule products: lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Immunic, Inc. to Participate in Industry and Investor Conferences in June
Read More
Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
Read More
BEAT-COV Endorses Initiative of the German Government for EUR 300 Million Funding Program for Late-Stage COVID-19 Therapies (in German Only)
Read More